STANDARD OF CARE TEMOZOLOMIDE CHEMOTHERAPY ± TUMOR TREATING FIELDS (TTFIELDS) IN NEWLY DIAGNOSED GLIOBLASTOMA. FINAL RESULTS OF THE PHASE III EF-14 CLINICAL TRIAL

被引：0
|
作者：
Stupp, R. [1 ,2 ]
Ram, Z. [3 ]
机构：
[1] Univ Zurich, Zurich, Switzerland
[2] EF 14 Investigators, Zurich, Switzerland
[3] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
来源：
NEURO-ONCOLOGY | 2017年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OS07.9
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [21] Tumor treating fields (TTFields) in combination with Lomustine (CCNU) in the EF-14 phase III clinical study: A safety analysis
    Kinzel, Adrian
    Lavy-Shahaf, Gitit
    Kirson, Eilon D.
    CANCER RESEARCH, 2018, 78 (13)
  • [22] Tumor Treating Fields alters progression patterns in glioblastoma: An imaging analysis of the EF-14 Phase III trial
    Jeyapalan, Suriya
    Toms, Steven A.
    Hottinger, Andreas
    Kleinberg, Lawrence
    Pollom, Erqi
    Soltys, Scott G.
    Glas, Martin
    CANCER RESEARCH, 2019, 79 (13)
  • [23] EFFECTS OF TUMOR TREATING FIELDS ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN NEWLY DIAGNOSED GLIOBLASTOMA: AN EXPLORATORY ANALYSIS OF THE EF-14 RANDOMIZED PHASE III TRIAL
    Walbert, T.
    Lavy-Shahaf, G.
    NEURO-ONCOLOGY, 2018, 20 : 242 - 242
  • [24] EFFECTS OF TUMOR TREATING FIELDS ON HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN NEWLY DIAGNOSED GLIOBLASTOMA: AN EXPLORATORY ANALYSIS OF THE EF-14 RANDOMIZED PHASE III TRIAL
    Walbert, Tobias
    Lavy-Shahaf, Gitit
    NEURO-ONCOLOGY, 2018, 20 : 214 - 214
  • [25] Clinical efficacy of tumor-treating fields for newly diagnosed glioblastoma.
    Liu, Yang
    Richardson, Margie
    Warren, Kwanza
    Strawderman, Myla S.
    Mohile, Nimish
    Milano, Michael T.
    Walter, Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] TUMOR TREATING FIELDS (TTFIELDS) THERAPY WITH CHEMORADIATION, FOLLOWED BY MAINTENANCE TTFIELDS THERAPY/TEMOZOLOMIDE (TMZ), IN NEWLY DIAGNOSED GLIOBLASTOMA (NDGBM). RESULTS OF PHASE II CLINICAL STUDY
    Grossman, Rachel
    NEURO-ONCOLOGY, 2024, 26
  • [27] AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
    Chinot, O. L.
    Wick, W.
    Saran, F.
    Mason, W. P.
    Henriksson, R.
    Nishikawa, R.
    Zeaiter, A. H.
    Moore, N.
    Das, A.
    Cloughesy, T. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] EF-32 (TRIDENT): A pivotal phase 3 randomized trial of concomitant radiation therapy and temozolomide plus /- Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma
    Glas, M.
    Kleinberg, L.
    Jeyapalan, S.
    Goldlust, S.
    Nagpal, S.
    Combs, S.
    Roberge, D.
    Nishikawa, R.
    Reardon, D.
    Grossman, R.
    Shi, W.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S97 - S98
  • [29] PHASE 3 TRIDENT TRIAL: CONCOMITANT RADIATION THERAPY (RT) AND TEMOZOLOMIDE plus /- TUMOR TREATING FIELDS (TTFIELDS) IN NEWLY DIAGNOSED GLIOBLASTOMA
    Shi, Wenyin
    Kleinberg, Lawrence
    Jeyapalan, Suriya A.
    Goldlust, Samuel
    Nagpal, Seema
    Combs, Stephanie E.
    Roberge, David
    Nishigawa, Ryo
    Grossman, Rachel
    Glas, Martin
    NEURO-ONCOLOGY, 2020, 22 : 59 - 60
  • [30] Tumor treating fields (TTFields) on health-related quality of life (HRQoL) in ndGBM: An exploratory analysis of the EF-14 phase III trial
    Walbert, Tobias
    Lavy-Shahaf, Gitit
    Toms, Steven A.
    Kesari, Santosh
    CANCER RESEARCH, 2018, 78 (13)
12345